Gene Bridges Licenses Recombination Technology to Takeda Pharmaceutical | GenomeWeb

Gene Bridges Licenses Recombination Technology to Takeda Pharmaceutical

Oct 07, 2008

NEW YORK (GenomeWeb News) – Gene Bridges said today that Osaka, Japan-based drug developer Takeda Pharmaceutical will use Gene Bridges’ recombination technology under a commercial license agreement through its Japanese distributor, Funakoshi.

Gene Bridges’ Red/ET recombination technology is used to generate target vectors or to modify E. coli chromosomes. The Red/ET technology allows for engineering of molecules, BACs, or the E. Coli chromosome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Embryos Edited in US

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

True Blue

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

All the Plants

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

This Week in Nature

In Nature this week: a Danish reference genome, and more.